Keensight Capital Acquires Majority Stake in Isto Biologics

Isto Biologics (TSCP Portfolio) Acquires TheraCell

April 5, 2022

Medical Devices

Isto Biologics, a portfolio company of Thompson Street Capital Partners, has acquired TheraCell, a Los Angeles–based regenerative medicine company known for its TheraFuze DBF bone-fiber technology. The deal expands Isto's orthobiologics product portfolio—adding TheraCell's proprietary spinal repair technologies to Isto's Influx line—and aims to accelerate surgical adoption through Isto's commercial and clinical teams. Terms were not disclosed.

Keensight Capital Takes Majority Stake in Adista from Equistone

June 15, 2021

IT Services

Keensight Capital has signed an agreement to acquire a majority stake in Adista, the leading French alternative B2B hosted services operator, taking over Equistone Partners Europe as majority shareholder alongside FEF and Adista management. Adista — a French IT and telecom services provider with more than 720 employees and 35 branches, €153m in revenues for the 12 months to 31/12/2020 and a target of €300m by 2025 — will be supported by Keensight to accelerate organic growth and pursue external growth / capability expansion.

Envista Acquires Osteogenics Biomedical Business

May 17, 2022

Medical Devices

Envista Holdings Corporation entered into a definitive agreement to acquire Osteogenics Biomedical, Allotech LLC and OBI Biologics (collectively “Osteogenics”), a developer of regenerative dental bone grafting products sold primarily under the Cytoplast brand. The deal, subject to customary regulatory approvals and expected to close in the third quarter, expands Envista’s capabilities in regenerative solutions for periodontists, oral and maxillofacial surgeons and implant dentistry; the transaction is not subject to a financing condition or shareholder vote.

Keensight Capital Acquires Majority Stake in Bedfont Scientific Ltd.

October 13, 2025

Medical Devices

Keensight Capital has acquired a majority stake in Bedfont Scientific Ltd., a UK-based designer and manufacturer of non-invasive breath analysis medical devices. The investment will support Bedfont's international expansion, product innovation and potential M&A-driven growth while existing shareholders reinvest alongside Keensight.

IK Partners Acquires Majority Stake in BIOBank

May 29, 2024

Medical Devices

IK Partners (via its IK Small Cap III fund) has agreed to acquire a majority stake in French tissue bank BIOBank from Verto Growth, Capital Croissance and management, who will reinvest. BIOBank, headquartered in Lieusaint, France, is a leading processor and distributor of bone allografts for orthopaedic, spine, dental and cranio‑maxillofacial surgery; IK plans to support market-share gains in France, accelerate international expansion and pursue a buy‑and‑build strategy.

Keensight Capital Acquires Majority Stake in BYG4lab

July 22, 2022

Software

Keensight Capital has acquired a majority stake in BYG4lab, a France-headquartered provider of data management software for medical laboratories. The PE firm will support BYG4lab's international expansion (Europe and North America), product diversification and accelerated growth both organically and via acquisitions.